We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Eidogen-Sertanty Licenses Target Informatics Platform to AstraZeneca
News

Eidogen-Sertanty Licenses Target Informatics Platform to AstraZeneca

Eidogen-Sertanty Licenses Target Informatics Platform to AstraZeneca
News

Eidogen-Sertanty Licenses Target Informatics Platform to AstraZeneca

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eidogen-Sertanty Licenses Target Informatics Platform to AstraZeneca"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eidogen-Sertanty, Inc. has announced that AstraZeneca Pharmaceuticals LP has licensed access to its Target Informatics Platform™.

Under the agreement, scientists at AstraZeneca R&D Boston will access Eidogen-Sertanty’s Target Informatics Platform (TIP™) and EVE™ Comparative Visualization software to assist drug discovery efforts within their cancer and anti-infective therapeutic programs.

Through the integration of protein structural data and ligand binding site analysis, TIP is designed to bridge the knowledge gap between the disciplines of bioinformatics and cheminformatics.

"We are very excited that AstraZeneca R&D Boston has selected TIP to assist their drug discovery efforts," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.

"We’re confident that TIP will help AstraZeneca scientists accelerate lead discovery programs across a wide variety of target families and therapeutic areas."

Advertisement